HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waxman, A. Articles by Braunstein, G. Search for Related Content PubMed PubMed Citation Articles by Waxman, A. Articles by Braunstein, G.

The Significance of I-131 Scan Dose in Patients with Thyroid Cancer: Determination of Ablation: Concise Communication

Cedars-Sinai Medical Center, USC and UCLA Schools of Medicine, Los Angeles, California

Correspondence: For reprints contact: Alan Waxman, MD, Director, Dept. of Nuclear Medicine, Cedars-Sinai Medical Ctr., 8700 Beverly Blvd., Los Angeles, CA 90048.

ABSTRACT

Twenty-four patients with differentiated thyroid cancer were studied with diagnostic I-131 neck and chest scans after having undergone bilateral subtotal thyroidectomy and initial I-131 therapy with either 30- or 100- mCi doses. With an endogenous stimulation protocol, follow-up studies were performed with neck and chest scans using 2 and 10 mCi I-131. A 400% increase in sensitivity was found with a 10-mCi dose relative to a 2-mCi dose. Comparison with therapeutic doses of 30 and 100 mCi resulted in further increases in the detection of residual iodine-avid tissue.

We conclude that a 2-mCi or lower dose of I-131 is inadequate in evaluating residual iodine-avid tissue visually in patients with thyroid cancer. The study does not answer the critical question of whether it is necessary to treat a patient presenting a negative 2-mCi but a positive 10-mCi scan. It may be appropriate to define ablation visually as well as clinically, with further studies directed toward determining a treatment rationale in this patient population

This article has been cited by other articles:

				J. M. Woolfenden Thyroid Stunning Revisited J. Nucl. Med., September 1, 2006; 47(9): 1403 - 1405. [Full Text] [PDF]

				H. Q. Dam, S. M. Kim, H. C. Lin, and C. M. Intenzo 131I Therapeutic Efficacy Is Not Influenced by Stunning after Diagnostic Whole-Body Scanning Radiology, August 1, 2004; 232(2): 527 - 533. [Abstract] [Full Text] [PDF]

				M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Impact of 131I Diagnostic Activities on the Biokinetics of Thyroid Remnants J. Nucl. Med., April 1, 2004; 45(4): 619 - 625. [Abstract] [Full Text] [PDF]

				S. K. Gerard Whole-Body Thyroid Tumor 123I Scintigraphy J. Nucl. Med., May 1, 2003; 44(5): 852 - 852. [Full Text] [PDF]

				S E M Clarke Advances in radionuclide imaging: radionuclide imaging as a guide to therapy Imaging, September 1, 2001; 13(3): 171 - 184. [Abstract] [Full Text] [PDF]

				L. F. Morris, A. D. Waxman, and G. D. Braunstein The Nonimpact of Thyroid Stunning: Remnant Ablation Rates in 131I-Scanned and Nonscanned Individuals J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3507 - 3511. [Abstract] [Full Text] [PDF]

				M T. Bajen, S. Mane, A. Munoz, and J. Ramon Garcia Effect of a Diagnostic Dose of 185 MBq 131I on Postsurgical Thyroid Remnants J. Nucl. Med., December 1, 2000; 41(12): 2038 - 2042. [Abstract] [Full Text] [PDF]

				A. Z. Rudavsky and L. M. Freeman Treatment of Scan-Negative, Thyroglobulin-Positive Metastatic Thyroid Cancer Using Radioiodine 131I and Recombinant Human Thyroid Stimulating Hormone J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 11 - 14. [Full Text] [PDF]